Conference Proceedings

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.

Frances A Shepherd, Vassiliki Papadimitrakopoulou, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S Ramalingam, Tom John, Martin Sebastian, Willemijn Theelen, Gianluca Laus, Barbara Collins, Aleksandra Markovets, Kenneth S Thress, Geoffrey R Oxnard

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2018

Citation metrics